Implications of statin adverse effects in the elderly

Bibliography

• KANNEL WB: Cholesterol and risk of coronary heart disease and mortality in men. Clin. Chem. (1988) 34:B53–B59.
   PubMed Web of Science ®Google Scholar
• PSATY BM, ANDERSON M, KRONMAL RA et al.: The association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality: The Cardiovascular Health Study. I Am. Ceriatr. Soc. (2004) 52:1639–1647.
   PubMed Web of Science ®Google Scholar
• LI JZ, CHEN ML, WANG S et al: A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly. Chin. Med. J. (Engl) (2004) 117:163–167.
   PubMed Web of Science ®Google Scholar
• CASIGLIA E, MAZZA A, TIKHONOFF V et al.: Total cholesterol and mortality in the elderly. J. Intern. Med. (2003) 254:353–362.
   PubMed Web of Science ®Google Scholar
• HOUTERMAN S, VERSCHUREN WM, GIAMPAOLI S et al.: Total but not high-density lipoprotein cholesterol is consistently associated with coronary heart disease mortality in elderly men in Finland, Italy, and The Netherlands. Epidemiology (2000) 11:327–332.
   PubMed Web of Science ®Google Scholar
• DYER AR, STAMLER J, SHEKELLE RB: Serum cholesterol and mortality from coronary heart disease in young, middle-aged, and older men and women from three Chicago epidemiologic studies. Ann. Epidemiol (1992) 2:51–57.
   PubMedGoogle Scholar
• BO M, FIANDRA U, FONTE G, BOBBIO M, FABRIS F: Cholesterol and long-term mortality after acute myocardial infarction in elderly patients. Age. Ageing (1999) 28:313–315.
   PubMed Web of Science ®Google Scholar
• KRUMHOLZ HM, SEEMAN TE, MERRILL SS et al.: Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA (1994) 272:1335–1340.
   PubMed Web of Science ®Google Scholar
• FAGARD R: Serum cholesterol levels and survival in elderly hypertensive patients: analysis of data from the European Working Party on High Blood Press, in the Elderly. Am. J. Med. (1991) 90:62S–63S
   Google Scholar
• WEIJENBERG MP, FESKENS EJ, BOWLES, CH, KROMHOUT D: Serum total cholesterol and systolic blood pressure as risk factors for mortality from ischemic heart disease among elderly men and women. I Clin. Epidemiol (1994) 47:197–205.
   PubMed Web of Science ®Google Scholar
• ULMER H, KELLEHER C, DIEM G, CONCIN H: Why Eve is not Adam: prospective follow-up in 149650 women and men of cholesterol and other risk factors related to cardiovascular and all-cause mortality. J. Womens Health (Larchmt) (2004) 13:41–53.
   PubMed Web of Science ®Google Scholar
• SHIPLEY MJ, POCOCK SJ, MARMOT MG: Does plasma cholesterol concentration predict mortality from coronary heart disease in elderly people? 18 year follow up in Whitehall study. BMI (1991) 303:89–92.
   PubMed Web of Science ®Google Scholar
• STRANDBERG TE, STRANDBERG A, RANTANEN K et al: Low cholesterol, mortality, and quality of life in old age during a 39-year follow-up. I Am. Coll. Cardiol (2004) 44:1002–1008.
   PubMed Web of Science ®Google Scholar
• CRIQUI MH, GOLOMB BA: Low and lowered cholesterol and total mortality. J. Am. Coll. Cardiol (2004) 44:1009–1010.
   PubMed Web of Science ®Google Scholar
• FRIED LP, KRONMAL RA, NEWMAN AB et al.: Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA (1998) 279:585–592.
   PubMed Web of Science ®Google Scholar
• FOODY JM, WANG Y, KIEFE CI et al: Long-term prognostic importance of total cholesterol in elderly survivors of an acute myocardial infarction: the Cooperative Cardiovascular Pilot Project. I Am. Ceriatr. Soc. (2003) 51:930–936.
   PubMed Web of Science ®Google Scholar
• PALATINI P, THUS L, STAESSEN JA et al.: Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch. Intern. Med. (2002) 162:2313–2321.
   PubMed Web of Science ®Google Scholar
• TERVAHAUTA M, PEKKANEN J, NISSINEN A: Risk factors of coronary heart disease and total mortality among elderly men with and without preexisting coronary heart disease. Finnish cohorts of the Seven Countries Study. I Am. Coll. Cardiol (1995) 26:1623–1629.
   PubMed Web of Science ®Google Scholar
• MENOTTI A, MULDER I, NISSINEN A et al.: Cardiovascular risk factors and 10-year all-cause mortality in elderly European male populations; the FINE study. Finland, Italy, Netherlands, Elderly. Eur. Heard: (2001) 22:573–579.
   Google Scholar
• CHYOU PH, EAKER ED: Serum cholesterol concentrations and all-cause mortality in older people. Age. Ageing (2000) 29:69–74.
   PubMed Web of Science ®Google Scholar
• BURSZTYN M, GINSBERG G, SPILBERG 0, MAARAVI Y, STESSMAN J: Mortality in the Jerusalem 70-year-olds longitudinal study: does nifedipine have a role? Ceriam Nephrol Urol (1999) 9:5–10.
   Google Scholar
• GUIZE L, BENETOS A, THOMAS F, MALMEJAC A, DUCIMETIERE P: [Cholesterolemia and total, cardiovascular and cancer mortality. Study of a cohort of 220,000 people]. Bull. Acad. Natl. Med. (1998) 182:631-647; discussion 647–650.
   Google Scholar
• SORELLE R: Death rate higher in elderlywith low cholesterol. Circulation (2001) 104:E9011–E9013.
   Google Scholar
• SCHATZ IJ, MASAKI K, YANO K et al: Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet (2001) 358:351–355.
   PubMed Web of Science ®Google Scholar
• WEVERLING-RIGNSBURGER AWE, BLAUW GJ, LAGAAY AM et al: Total cholesterol and risk of mortality in the oldest old. Lancet (1997) 350:1119–1123.
   PubMed Web of Science ®Google Scholar
• •Persons > 85 years of age, show a sharp inverse relationship of cholesterol to mortality.
   Google Scholar
• MARAFON LP, DA CRUZ IB, SCHWANKE CH, MORIGUCHI EH: [Cardiovascular mortality predictors in the oldest old]. Cad Saude Publica (2003) 19:799–807.
   PubMedGoogle Scholar
• NEWSCHAFFER CJ, BUSH TL, HALE WE: Aging and total cholesterol levels: cohort, period, and survivorship effects. Am. J. Epidemiol (1992) 136:23–34.
   PubMed Web of Science ®Google Scholar
• BOLOGA RM, LEVINE DM, PARKER TS et al: Interleukin-fl predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am. J. Kidney Dis. (1998) 32:107–114.
   PubMed Web of Science ®Google Scholar
• FRAUNBERGER P, PILZ G, CREMER P, WERDAN K, WALLI AK: Association of serum tumor necrosis factor levels with decrease of cholesterol during septic shock. Shock (1998) 10:359–363.
   PubMed Web of Science ®Google Scholar
• LOPEZ MARTINEZ J, SANCHEZ CASTILLA M, ORDONEZ GONZALEZ FJ et al: The usefulness of cholesterol as a nutritional-metabolic marker in the septic patient. Nutr. Hosp. (1995) 10:24–31.
   PubMedGoogle Scholar
• HENRY 0, JOURDAN B, DUVIQUET M: [Analysis of the inflammatory response in elderly hospitalized patients]. Ann. Med. Interne (Paris) (1999) 150:189–194.
   PubMedGoogle Scholar
• HU P, SEEMAN TB, HARRIS TB, REUBEN DB: Does inflammation or undernutrition explain the low cholesterol-mortality association in high-functioning older persons? MacArthur studies of successful aging. J. Am. Geriatr. Soc. (2003) 51:80–84.
   PubMed Web of Science ®Google Scholar
• PFRIEGER FW: Role of glia in synapse development. Curr. Opin. Neurobiol (2002) 12:486–490.
   PubMed Web of Science ®Google Scholar
• GORITZ C, MAUCH DH, NAGLER K, PFRIEGER FW: Role of glia-derived cholesterol in synaptogenesis: new revelations in the synapse-glia affair. Physiol. Paris (2002) 96:257–263.
   PubMed Web of Science ®Google Scholar
• JACOBS D, BLACKBURN H, HIGGINS M et al: Report of the Conference on Low Blood Cholesterol: Mortality Associations. Circulation (1992) 86:1046–1060.
   PubMed Web of Science ®Google Scholar
• GOTTO JR AM JR, FARMER JA: Pleiotropic effects of statins: do they matter? Curr. Opin. Lipidol. (2001) 12:391–394.
   Web of Science ®Google Scholar
• TAKEMOTO M, LIAO JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. (2001) 21:1712–1719.
   PubMed Web of Science ®Google Scholar
• NOVELA C, HENNEKENS CH: Hypothesis: atorvastatin has pleiotropic effects that translate into early clinical benefits on cardiovascular disease. Cardiovasc. Pharmacol Ther. (2004) 9:61–63.
   PubMed Web of Science ®Google Scholar
• SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383–1389.
   PubMed Web of Science ®Google Scholar
• DOWNS JR, CLEARFIELD M, WEIS S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study [see comments]. JAMA (1998) 279:1615–1622.
   Google Scholar
• SHEPHERD J, BLAUW GJ, MURPHY MB et al: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (2002) 360:1623–1630.
   PubMed Web of Science ®Google Scholar
• ••The sole randomised trial targeted toelderly (> 70 years of age) showed no trend toward mortality benefit and a significant increase in cancer in those assigned to statins.
   Google Scholar
• Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA (2002) 288:2998–3007.
   PubMed Web of Science ®Google Scholar
• KO DT, MAMDANI M, ALTER DA: Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA (2004) 291:1864–1870.
   PubMed Web of Science ®Google Scholar
• GHOSH S, ARONOW WS: Utilization of lipid-lowering drugs in elderly persons with increased serum low-density lipoprotein cholesterol associated with coronary artery disease, symptomatic peripheral arterial disease, prior stroke, or diabetes mellitus before and after an educational program on dyslipidemia treatment. I Gerontol A. Biol. Li. Med. Li. (2003) 58: M432–M435.
   PubMedGoogle Scholar
• HOLME I, TONSTAD S: Treatment with statins of the elderly. Tidsskr. Nor. Laegeforen. (2004) 124:167–169.
   PubMedGoogle Scholar
• PLAYFORD DA, WATTS GF: Management of lipid disorders in the elderly. Drugs Aging (1997) 10:444–462.
   PubMed Web of Science ®Google Scholar
• NASH DT: Statins. Evidence of effectiveness in older patients. Geriatrics (2003) 58:35-36, 39–42.
   Google Scholar
• DE WILDE S, COOK DG, CAREY IM, HILTON SR, WHINCUP PH: Underuse of statins among older people. Lancet (2003) 362:746–747.
   PubMed Web of Science ®Google Scholar
• Statins safe for elderly patients. New findings offer reassurance about the cholesterol drugs. Heart Advis. (2003) 6:3.
   Google Scholar
• Serious adverse event analysis: Lipid-lowering therapy revisited. Therapeutics Letter (2001) 42:1–2.
   Google Scholar
• LEIPZIG RM: Avoiding adverse drug effects in elderly patients. Cleve. Clin. Med. (1998) 65:470–478.
   PubMed Web of Science ®Google Scholar
• O'BRIEN JG, KURSCH JE: 'Healthy' prescribing for the elderly. How to minimize adverse drug effects and prevent 'dementia in a bottle'. Postgrad. Med. (1987) 82:147-151, 154, 156 passim
   Google Scholar
• PELTON R, LA VALLE JB, HAWKINS EB, KRINSKY DL: Drug-induced nutrient depletion handbook, 2nd Ed. Hudson OH: Lexi-Comp's Clinicaal Reference Library (2001)
   Google Scholar
• PASTERNAK RC, SMITH SC, BAIREY-MERZ CN et al: ACC/AHA/ NHLBI Clinical Advisory on the Use and Safety of Statins. .1 Am. Coll. Cardiol (2002) 40:568–573.
   Google Scholar
• ROCK CL, THORNQUIST MD, KRISTAL AR et al: Demographic, dietary and lifestyle factors differentially explain variability in serum carotenoids and fat-soluble vitamins: baseline results from the sentinel site of the Olestra Post-Marketing Surveillance Study. Nutr. (1999) 129:855–864.
   Web of Science ®Google Scholar
• MORTENSEN SA, LETH A, AGNER E, ROHDE M: Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med. (1997) 18 (Suppl.):S137–S144.
   Google Scholar
• •Shows that statins lead to dose-related reduction in serum Q10.
   Google Scholar
• RUNDEK T, NAINI A, SACCO R, COATES K, DIMAURO S: Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch. Neurol (2004) 61:889–892.
   PubMed Web of Science ®Google Scholar
• •Atorvastatin (80mg/day), now the best-selling prescription drug in the world, leads to a brisk and marked reduction in Q10 levels.
   Google Scholar
• IBRAHIM WH, BHAGAVAN HN, CHOPRA RK, CHOW CK: Dietary coenzyme Q10 and vitamin E alter the status of these compounds in rat tissues and mitochondria. J. Nutr. (2000) 130:2343–2348.
   PubMed Web of Science ®Google Scholar
• ENGLAND JD, WALSH JC, STEWART P et al: Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors-simvastatin and pravastatin [letter]. Aust. NZ J. Med. (1995) 25:374–375.
   PubMedGoogle Scholar
• •Possibly the first description of statin muscle symptoms as a mitochondrial myopathy.
   Google Scholar
• GOLI AK, GOLI SA, BYRD RP JR, ROY TM: Simvastatin-induced lactic acidosis: a rare adverse reaction? Clin. Pharmacol Ther. (2002) 72:461–464.
   Web of Science ®Google Scholar
• NEALE R, REYNOLDS TM, SAWEIRS W: Statin precipitated lactic acidosis?' Clin. Pathol (2004) 57:989–990.
   Web of Science ®Google Scholar
• DE PINIEUX G, CHARIOT P, AMMI-SAID M et al: Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/ pyruvate ratio. BE J. Clin. Pharmacol (1996) 42:333–337.
   PubMed Web of Science ®Google Scholar
• CHARIOT P, ABADIA R, AGNUS D et al.: Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am. J. Med. (1993) 94:109–110.
   PubMed Web of Science ®Google Scholar
• PHILLIPS PS, PHILLIPS CT, SULLIVAN MJ, NAVIAUX RK, HAAS RH: Statin myotoxicity is associated with changes in the cardiopulmonary function. Atherosclerosis (2004) 177:183–188.
   PubMed Web of Science ®Google Scholar
• PHILLIPS PS, HAAS RH, BANNYKH S et al.: Statin-associated myopathy with normal creatine kinase levels. Ann. Intern. Med. (2002) 137:581–585.
   PubMed Web of Science ®Google Scholar
• •Double-blind cross-over biopsy study showing that non-CK elevating muscle symptoms on statins (or those that minimally elevate CK) represent a partially reversible mitochondrial myopathy.
   Google Scholar
• SINZINGER H, CHEHNE F, LUPATTELLI G: Oxidation Injury in Patients Receiving HMG-CoA Reductase Inhibitors: Occurrence in Patients Without Enzyme Elevation or Myopathy. Drug Sal (2002) 25:877–883.
   PubMed Web of Science ®Google Scholar
• PHILLIPS CT, GRAY NL, PUHEK LM et al.: Basal Respiratory Exchange Ratio Is Altered With Statin Use in Normals [abstract]. J. Am. Coll. Cardiol. (2004) 43 (Suppl A):233a
   Google Scholar
• BLIZNAKOV EG: Aging, mitochondria, and coenzyme Q(10): the neglected relationship. Biochimie (1999) 81:1131–1132.
   PubMed Web of Science ®Google Scholar
• SINGH KK: Mitochondrial dysfunction isa common phenotype in aging and cancer. Ann. NY Acad. Sci. (2004) 1019:260–264.
   PubMed Web of Science ®Google Scholar
• HUANG H, MANTON KG: The role of oxidative damage in mitochondria during aging: a review. Front Biosci. (2004) 9:1100–1117.
   PubMed Web of Science ®Google Scholar
• MANDAVILLI BS, SANTOS JH, VAN HOUTEN B: Mitochondrial DNA repair and aging. Mutat Res. (2002) 509:127–151.
   PubMed Web of Science ®Google Scholar
• LENAZ G, BOVINA C, D'AURELIO M et al.: Role of mitochondria in oxidative stress and aging. Ann. NY Acad. Sri. (2002) 959:199–213.
   PubMed Web of Science ®Google Scholar
• VAN REMMEN H, RICHARDSON A: Oxidative damage to mitochondria and aging. Exp. Cerontol. (2001) 36:957–968.
   PubMed Web of Science ®Google Scholar
• SALVIOLI S, BONAFE M, CAPRI M, MONTI D, FRANCESCHI C: Mitochondria, aging and longevity-a new perspective. FEBS Lett. (2001) 492:9–13.
   PubMed Web of Science ®Google Scholar
• POLLACK M, LEEUWENBURGH C: Apoptosis and aging: role of the mitochondria. J. Cerontol A. Biol. Sri. Med. Sri. (2001) 56: B475–B482.
   PubMed Web of Science ®Google Scholar
• EBADI M: Introduction. Oxidative stress in mitochondria disorders of aging. Biol. Signals Recept. (2001) 10:5–13.
   Google Scholar
• BERDANIER CD, EVERTS HB: Mitochondrial DNA in aging and degenerative disease. Mutat. Res. (2001) 475:169–183.
   PubMed Web of Science ®Google Scholar
• SASTRE J, PALLARDO FV, GARCIA DE LA ASUNCION J, VINA J: Mitochondria, oxidative stress and aging. Free Radic. Res. (2000) 32:189–198.
   PubMed Web of Science ®Google Scholar
• LENAZ G, D'AURELIO M, MERLO PICH M et al: Mitochondrial bioenergetics in aging. Biochim. Biophys. Acta (2000) 1459:397–404.
   PubMed Web of Science ®Google Scholar
• LEE HC, WEI YH: Role of Mitochondria in Human Aging. I Biomed. Sri. (1997) 4:319–326.
   PubMed Web of Science ®Google Scholar
• MIQUEL J: An update on the mitochondrial-DNA mutation hypothesis of cell aging. Mutat Res. (1992) 275:209–216.
   PubMed Web of Science ®Google Scholar
• LINNANE AW: Mitochondria and aging: the universality of bioenergetic disease. Aging (Milano) (1992) 4:267–271.
   PubMedGoogle Scholar
• BANDY B, DAVISON AJ: Mitochondrial mutations may increase oxidative stress: implications for carcinogenesis and aging? Free Radic. Biol. Med. (1990) 8:523–539.
   Google Scholar
• TOLEDANO A: Mitochondria, brain aging and neurodegenerative disorders. Aging (Milano) (1993) 5:459–461.
   PubMedGoogle Scholar
• OZAWA T: Mitochondrial DNA mutations associated with aging and degenerative diseases. Exp. Cerontol (1995) 30:269–290.
   PubMed Web of Science ®Google Scholar
• KALOUS M and DRAHOTA Z: The role of mitochondria in aging. Physiol Res. (1996) 45:351–359.
   PubMed Web of Science ®Google Scholar
• GADALETA MN, CORMIO A, PESCE V, LEZZA AM, CANTATORE P: Aging and mitochondria. Biochimie (1998) 80:863–870.
   PubMed Web of Science ®Google Scholar
• SINZINGER H, SCHMID P, O'GRADY J: Two different types of exercise-induced muscle pain without myopathy and CK -elevation during HMG-Co-enzyme-A-reductase inhibitor treatment. Atherosclerosis (1999) 143:459–460.
   PubMed Web of Science ®Google Scholar
• HARADA K, TSURUOKA S, FUJIMURA A: Shoulder stiffness: a common adverse effect of HMG-CoA reductase inhibitors in women? Intern. Med. (2001) 40:817–818.
   Web of Science ®Google Scholar
• UCAR M, MJORNDAL T, DAHLQVIST R: HMG-CoA reductase inhibitors and myotoxicity. Drug Sal (2000) 22:441–457.
   PubMed Web of Science ®Google Scholar
• ENGLAND JD, VILES A, WALSH JC, STEWART PM: Muscle side effects associated with simvastatin therapy [letter]. Med. J. Aust. (1990) 153:562–563.
   PubMed Web of Science ®Google Scholar
• SINZINGER H, O'GRADY J: Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br. J. Clia Pharmacol (2004) 57:525–528.
   PubMed Web of Science ®Google Scholar
• FAUCHAIS AL, IBA BA J, MAURAGE P et al.: [Polymyositis induced or associated with lipid-lowering drugs: five cases]. Rev Med. Interne (2004) 25:294–298.
   PubMed Web of Science ®Google Scholar
• GIORDANO N, SENESI M, MATTII G et al.: Polymyositis associated with simvastatin. Lancet (1997) 349:1600–1601.
   PubMed Web of Science ®Google Scholar
• HILL C, ZEITZ C, KIRKHAM B: Dermatomyositis with lung involvement in a patient treated with simvastatin. Aust. NZ J. Med. (1995) 25:745–746.
   PubMedGoogle Scholar
• KHATTAK FH, MORRIS IM, BRANFORD WA: Simvastatin-associated dermatomyositis. BE J. Rheumatol (1994) 33:199.
   PubMedGoogle Scholar
• NOEL B, CEROTTINI JP, PANIZZON RG: Atorvastatin-induced dermatomyositis. Am. J. Med. (2001) 110:670–671.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ-GARCIA JL, SERRANO COMMINO M: Lovastatin-associated dermatomyositis. Postgrad. Med. J. (1996) 72:694.
   PubMed Web of Science ®Google Scholar
• SCALVINI T, MAROCOLO D, CERUDELLI B et al.: Pravastatin-associated myopathy. Report of a case. Recenti Frog. Med. (1995) 86:198–200.
   PubMedGoogle Scholar
• MULDOON ME BARGER SD, RYAN CM et al: Effects of lovastatin on cognitive function and psychological well-being. Am. J. Med. (2000) 108:538–546.
   PubMed Web of Science ®Google Scholar
• •Randomised trial reporting significant reduction in cognitive function with statin versus placebo.
   Google Scholar
• MULDOON ME RYAN CM, SEREIKA SM, FLORY JD, MANUCK SB: Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am.). Med. (2004) 117:823–829.
   PubMed Web of Science ®Google Scholar
• •Randomised trial reporting significant reduction in cognitive function with statin versus placebo.
   Google Scholar
• WAGSTAFF LR, MITTON MW, ARVIK BM, DORAISWAMY PM: Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy (2003) 23:871–880.
   PubMed Web of Science ®Google Scholar
• •Series of cases of cognitive adverse effects reported to the FDA.
   Google Scholar
• KING DS, JONES EW, WOFFORD MR, et al.: Cognitive impairment associated with atorvastatin. Pharmacotherapy (2001) 21:371 Abstract 336.
   Google Scholar
• KING DS, WILBURN AJ, WOFFORD MR et al.: Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy (2003) 23:1663–1667.
   PubMed Web of Science ®Google Scholar
• GOLOMB BA, CRIQUI MH, WHITE H, DIMSDALE JE: Conceptual foundations of the UCSD Statin Study: a randomized controlled trial assessing the impact of statins on cognition, behavior, and biochemistry. Arch. Intern. Med. (2004) 164:153–162.
   PubMed Web of Science ®Google Scholar
• •Reviews evidence relating statins to cognitive function.
   Google Scholar
• GOLOMB BA, CRIQUI MH, WHITE HL, DIMSDALE JE: The UCSD Statin Study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes. Control. Chi]. Trials (2004) 25:178–202.
   PubMedGoogle Scholar
• •Discusses factors that may have contributed to discrepancies among clinical trials in findings related to cognition.
   Google Scholar
• GOLOMB BA, KANE T, DIMSDALE JE: Severe irritability associated with statin cholesterol-lowering drugs. WM (2004) 97:229–235.
   Google Scholar
• GOLOMB BA, MCGRAW J: Subjects' report of physicians' response to statin drug adverse effects. (2005) In press.
   Google Scholar
• NARANJO CC, BUSTO U, SELLERS EM, et al.: A method for estimating the probability of adverse drug reactions. Clin. Pharmacol Ther. (1981) 30:239–245.
   Google Scholar
• NEWMAN TB, HULLEY SB: Carcinogenicity of lipid-lowering drugs. JAMA (1996) 275:55–60.
   PubMed Web of Science ®Google Scholar
• CHING S, INGRAM D, HAHNEL R, BEILBY J, ROSSI E: Serum levels of micronutrients, antioxidants and total antioxidant status predict risk of breast cancer in a case control study. J. Num. (2002) 132:303–306.
   Google Scholar
• WILLIAMS RR, SORLIE PD, FEINLEIB M et al: Cancer incidence by levels of cholesterol. JAMA (1981) 245:247–252.
   PubMed Web of Science ®Google Scholar
• ISLES C, HOLED, GILLIS C, HAWTHORNE V, LEVER A: Plasma cholesterol, coronary heart disease, and cancer in the Renfrew and Paisley survey. Br. Med. J. (1989) 298:920–924.
   PubMed Web of Science ®Google Scholar
• SCHATZKIN A, HOOVER R, TAYLOR P et al.: Site-specific analysis of total serum cholesterol and incident cancer in the National Health and Nutrition Examination Survey I Epidemiological Follow-Up Study. Cancer Res. (1988) 48:452–458.
   PubMed Web of Science ®Google Scholar
• CHANG AK, BARRETT-CONNOR E, EDELSTEIN S: Low plasma cholesterol predicts an increased risk of lung cancer in elderly women. Prey. Med. (1995) 24:557–562.
   PubMed Web of Science ®Google Scholar
• KREGER BE, ANDERSON KM, SCHATZKIN A, SPLANSKY GL: Serum cholesterol level, body mass index, and the risk of colon cancer. The Framingham Study. Cancer (1992) 70:1038–1043.
   PubMed Web of Science ®Google Scholar
• SHERWIN R, WENTWORTH D, CUTLER J et al.: Serum cholesterol levels and cancer mortality in 361,662 men screened for the Multiple Risk Factor Intervention Trial. I Am. Med. Assoc. (1987) 257:943–948.
   PubMed Web of Science ®Google Scholar
• KAGAN T, DAVIS C, LIN L, ZAKERI Z: Coenzyme Q10 can in some circumstances block apoptosis, and this effect is mediated through mitochondria. Ann. NY Acad. Sci. (1999) 887:31–47.
   PubMed Web of Science ®Google Scholar
• PAPUCCI L, SCHIAVONE N, WITORT E et al: Coenzyme q10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property. J. Biol. Chem. (2003) 278:28220–28228.
   PubMed Web of Science ®Google Scholar
• DI GIOVANNI S, MIRABELLA M, SPINAZZOLA A et al: Coenzyme Q10 reverses pathological phenotype and reduces apoptosis in familial CoQ10 deficiency. Neurology (2001) 57:515–518.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ-AYALA DJ, MARTIN SF, BARROSO MP et al.: Coenzyme Q protects cells against serum withdrawal-induced apoptosis by inhibition of ceramide release and caspase-3 activation. Antioxid. Redox Signal (2000) 2:263–275.
   PubMed Web of Science ®Google Scholar
• BEAL MF: Coenzyme Q10 as a possible treatment for neurodegenerative diseases. Free Radic. Res. (2002) 36:455–460.
   PubMed Web of Science ®Google Scholar
• SHULTS CW, OAKES D, KIEBURTZ K et al.: Effects of coenzyme Q10 in early Parkinson's disease: evidence of slowing of the functional decline. Arch. Neurol (2002) 59:1541–1550.
   PubMed Web of Science ®Google Scholar
• •Q10 slows progression of early neurodegenerative disease (Parkinson's disease) in humans.
   Google Scholar
• MOLLER T, KUHN W, POHLAU D, PRZUNTEK H: Parkinsonism unmasked by lovastatin [letter]. Ann. Neurol (1995) 37:685–686.
   Web of Science ®Google Scholar
• VEDANARAYANAN VV: Mitochondrial disorders and ataxia. Semin Pediatr. Neurol (2003) 10:200–209.
   PubMedGoogle Scholar
• GUIRAUD-CHAUMEIL C, BATTAGLIA F, TRANCHANT C, WARTER JM: Spinocerebellar ataxia and polyneuropathy secondary to vitamin E deficiency. Presse Med. (1999) 28:524–526.
   PubMed Web of Science ®Google Scholar
• LAMPERTI C, NAINI A, HIRANO M et al: Cerebellar ataxia and coenzyme Q10 deficiency. Neurology(2003) 60:1206–1208.
   PubMed Web of Science ®Google Scholar
• MUSUMECI 0, NAINI A, SLONIM AE et al.: Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. Neurology (2001) 56:849–855.
   Google Scholar
• CRISTOFARI M, BERTOCCHI P, VIGANO M: [The MELAS syndrome and dilated-hypertrophic cardiomyopathy: a case report]. G. Ital. Cardiol (1995) 25:69–76.
   PubMedGoogle Scholar
• LERMAN-SAGIE T, RUSTIN P, LEV D et al.: Dramatic improvement in mitochondrial cardiomyopathy following treatment with idebenone. 1 Inherit. Metab. Dis. (2001) 24:28–34.
   Google Scholar
• MORTENSEN SA, VADHANAVIKIT S, MURATSU K, FOLKERS K: Coenzyme Q10: clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure. Int. J. Tissue React. (1990) 12:155–162.
   PubMedGoogle Scholar
• DROMER C, VEDRENNE C, BILLEY T et al.: Rhabdomyolysis due to simvastin. Apropos of a case with review of the literature. Rev Rhum. Mal. Osteoartic (1992) 59:281–283.
   PubMedGoogle Scholar
• SILVER MA, LANGSJOEN PH, SZABO S, PATIL H, ZELINGER A: Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am. J. Cardiol (2004) 94:1306–1310.
   PubMed Web of Science ®Google Scholar
• •Impairment in diastolic heart function in subjects placed on statins; restoration of function when Q10 is added. Intriguing preliminary information.
   Google Scholar
• JICK H, ZORNBERG GL, JICK SS, SESHADRI S, DRACHMAN DA: Statins and the risk of dementia. Lancet (2000) 356:1627–1631.
   PubMed Web of Science ®Google Scholar
• WOLOZIN B: Cholesterol and Alzheimer's disease. Biochem. Soc. Trans. (2002) 30:525–529.
   PubMed Web of Science ®Google Scholar
• SIMONS M, KELLER P, DICHGANS J, SCHULZ JB: Cholesterol and Alzheimer's disease: is there a link? Neurology (2001) 57:1089–1093.
   PubMed Web of Science ®Google Scholar
• KIRSCH C, ECKERT GP, KOUDINOV AR, MULLER WE: Brain cholesterol, statins and Alzheimer's disease. Pharmacopsychiatry (2003) 36 (Supp1.2):5113–5119.
   Google Scholar
• WOLOZIN B: Cholesterol, statins and dementia. Curr. Opin. Lipidol (2004) 15:667–672.
   PubMed Web of Science ®Google Scholar
• GOLOMB BA, JAWORSKI BA: Statins and dementia. Arch. Neurol (2001) 58:1169–1170.
   PubMed Web of Science ®Google Scholar
• •Theorised benefits of statins to Alzheimer's disease are compatible with statistical confounding and indication bias.
   Google Scholar
• SEED M: The choice of hormone replacement therapy or statin therapy in the treatment of hyperlipidemic postmenopausal women. Atheroscler. Suppl (2002) 3:53–63.
   PubMed Web of Science ®Google Scholar
• CHOLERTON B, GLEASON CE, BAKER LD, ASTHANA S: Estrogen and Alzheimer's disease: the story so far. Drugs Aging (2002) 19:405–427.
   PubMed Web of Science ®Google Scholar
• SHUMAKER SA, LEGAULT C, RAPP SR et al.: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA (2003) 289:2651–2662.
   PubMed Web of Science ®Google Scholar
• RAPP SR, ESPELAND MA, SHUMAKER SA et al.: Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA (2003) 289:2663–2672.
   PubMed Web of Science ®Google Scholar
• WARREN MP: A comparative review of the risks and benefits of hormone replacement therapy regimens. Am. J. Obstet. Gynecol (2004) 190:1141–1167.
   PubMed Web of Science ®Google Scholar
• SPARKS DL, CONNOR DJ, BROWNE PJ, LOPEZ JE, SABBAGH MN: HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier. I Nutr. Health Aging (2002) 6:324–331.
   PubMedGoogle Scholar
• SPARKS DL, MARTINS R, MARTIN T: Cholesterol and cognition: rationale for the AD cholesterol-lowering treatment trial and sex-related differences in beta-amyloid accumulation in the brains of spontaneously hypercholesterolemic Watanabe rabbits. Ann. NY Acad. Sri. (2002) 977:356–366.
   PubMed Web of Science ®Google Scholar
• SPARKS DL, MARTIN TA, GROSS DR, HUNSAKER JC, 3RD: Link between heart disease, cholesterol, and Alzheimer's disease: a review. Micrasc. Res. Tech. (2000) 50:287–290.
   PubMed Web of Science ®Google Scholar
• GURALNIK JM, SIMONSICK EM, FERRUCCI L et al.: A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. Gerontol (1994) 49:M85–M94.
   Web of Science ®Google Scholar
• MCDERMOTT MM, GREENLAND P, FERRUCCI L et al.: Lower extremity performance is associated with daily life physical activity in individuals with and without peripheral arterial disease. J. Am. Geriatr. Soc. (2002) 50:247–255.
   PubMed Web of Science ®Google Scholar
• GURALNIK JM, FERRUCCI L, PIEPER CF et al.: Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J. Gerontol A. Biol. Sci. Med. Sri. (2000) 55:M221–M231.
   PubMed Web of Science ®Google Scholar
• PENNINX BW, FERRUCCI L, LEVEILLE SG et al: Lower extremity performance in nondisabled older persons as a predictor of subsequent hospitalization. Gerontol A. Biol. Sci. Med. Sd. (2000) 55:M691–M697.
   PubMed Web of Science ®Google Scholar
• GURALNIK JM, FERRUCCI L, SIMONSICK EM, SALIVE ME, WALLACE RB: Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. N Engl. J. Med. (1995) 332:556–561.
   PubMed Web of Science ®Google Scholar
• BRUCE ML, HOFF RA, JACOBS SC, LEAF PJ: The effects of cognitive impairment on 9-year mortality in a community sample. I Gerontol B Psycho] Sri. Soc. Sri. (1995) 50:P289–P296.
   PubMed Web of Science ®Google Scholar
• ROZZINI R, FRANZONI S, FRISONI G, TRABUCCHI M: Cognitive impairment and survival in very elderly people. Decreased survival with cognitive impairment seems not be related to comorbidity [letter; comment]. BMI (Clinical Research Ed.) (1998) 316:164.
   Google Scholar
• GUSSEKLOO J, WESTENDORP RG, REMARQUE EJ et al: Impact of mild cognitive impairment on survival in very elderly people: cohort study [see comments]. BM I (Clinical Research Ed.) (1997) 315:1053–1054.
   PubMed Web of Science ®Google Scholar
• KORTEN AE, JORM AF, PAO Z et al: Health, cognitive, and psychosocial factors as predictors of mortality in an elderly community sample. I Epidemiol and Community Health (1999) 53:83–88.
   PubMed Web of Science ®Google Scholar
• FRISONI GB, FRATIGLIONI L, FASTBOM J, VIITANEN M, WINBLAD B: Mortality in nondemented subjects with cognitive impairment: the influence of health-related factors. Am. J. Epidemiol (1999) 150:1031–1044.
   PubMed Web of Science ®Google Scholar
• BOSHUIZEN HC, IZAKS GJ, VAN BUUREN S, LIGTHART GJ: Blood pressure and mortality in elderly people aged 85 and older: Community based study. BE Med. J. (1998) 316:1780–1784.
   PubMed Web of Science ®Google Scholar
• GILL TM, WILLIAMS CS, RICHARDSON ED, TINETTI ME: Impairments in physical performance and cognitive status as predisposing factors for functional dependence among nondisabled older persons. J. Gerontol A. Biol. Sri. Med. Sri. (1996) 51: M283–M288.
   PubMed Web of Science ®Google Scholar
• GILL TM, ROBISON JT, TINETTI ME: Predictors of recovery in activities of daily living among disabled older persons living in the community. I Gen. Intern. Med. (1997) 12:757–762.
   PubMed Web of Science ®Google Scholar